Contribution: Industrial Research Assistance Program – Contributions to Firms
Naegis Pharmaceuticals Inc.
$135,000.00
Leukotriene synthesis inhibitor compound efficacy and distribution profiling.
FY 2019-20 · 2019-04-01
Summary
This project involves preclinical studies that will be performed to support development of the firm's lead molecule, an inhibitor of leukotriene production, as a potential novel therapy for inflammatory eye diseases.
Department
Program
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (linked with high confidence)
Recipient
Location
Vancouver|Vancouver, British Columbia, Canada
Recipient Type
For-profit organization
Business Number
818181224
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
Amendments
Each version of the agreement as published, oldest first, with its total as of that version. The amount above is the latest.
| Amendment | Date | Fiscal Year | Total |
|---|---|---|---|
| 0 | 2019-04-01 | 2019-20 | $60,000.00 |
| 1 | 2019-04-01 | 2019-20 | $135,000.00 |
As published
Additional Information
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 28 days. The total amended value is 75,000 dollars.
Additional Information (French)
Cet accord a été modifié 1 fois La date de fin du présent accord a été changé de 28 jours. La valeur totale des modifications est de 75 000 dollars.
Agreement End Date
2020-02-28
Agreement Number
927212
Agreement Start Date
2019-04-01
Agreement Title
Leukotriene synthesis inhibitor compound efficacy and distribution profiling.
Agreement Title (French)
Efficacité d'inhibiteur de synthèse de leucotriène et profilage de leur distribution
Agreement Type
Contribution
Agreement Value
$135,000.00
Amendment Date
2019-09-04
Amendment Number
1
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
This project involves preclinical studies that will be performed to support development of the firm's lead molecule, an inhibitor of leukotriene production, as a potential novel therapy for inflammatory eye diseases.
Description (French)
Ce projet comprend des études précliniques, qui seront réalisées pour soutenir le développement de la molécule principale de l'entreprise, un inhibiteur de la production de leucotriène, comme traitement novateur potentiel des maladies oculaires inflammatoires.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
Vancouver Granville
Federal Riding (French)
Vancouver Granville
Federal Riding Number
59036
NAICS Code
541710
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
818181224
Recipient City
Vancouver|Vancouver
Recipient Country
CA
Recipient Legal Name
Naegis Pharmaceuticals Inc.
Recipient Postal Code
V5Z 1K5
Recipient Province or Territory
BC
Recipient Type
F
Reference Number
172-2019-2020-Q1-927212
